Pancreatic Cancer Treatment Market Size Report 2034 | AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics

DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of pancreatic cancer, historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Glioma Market with DelveInsight's In-Depth Report @ Glioma Market Size- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Pancreatic Cancer Market Report
• In February 2025:- Novartis Pharmaceuticals conducted a single-arm clinical study to evaluate the safety and efficacy of everolimus in Chinese adult patients with locally advanced, unresectable, or metastatic well-differentiated progressive pancreatic neuroendocrine tumors. The study's inclusion and exclusion criteria, along with the dosing and dose modification guidelines, were aligned with the approved Chinese Package Insert. The planned sample size for the study was approximately 60 subjects.
• In February 2025;- Lokon Pharma AB conducted a study to evaluate the safety of LOAd703, an oncolytic adenovirus, in patients with pancreatic cancer. The study also aims to determine whether intratumoral injection of LOAd703 can enhance the effectiveness of standard care treatment by reducing tumor size and improving patient survival.
• As per DelveInsight's estimates, total incident cases of pancreatic cancer in the United States was around 35% cases in 2023.
• The analysis from 2023 suggests that the stage-specific incident cases of pancreatic cancer in the US were maximum for distant, with nearly 50% cases, followed by regional and localized cases.
• The mutation types involved in pancreatic cancer include, KRAS2, TP53, SMAD4/DPC4, BRCA1/2, MSI-H/dMMR, and NTRK. In the United States, KRAS2 and TP53 accounted for the highest number of incident cases of pancreatic cancer in 2023.
• Among EU4 and the UK, the highest number of incident cases of pancreatic cancer was observed in the Germany in 2023, which is followed by France.
• The leading Pancreatic Cancer Companies such as AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others.
• Promising Pancreatic Cancer Therapies such as Napabucasin, Gemcitabine, Parvovirus H-1 (H-1PV), AG-013736, Antroquinonol, Lanreotide autogel 120 mg and others.

Stay ahead in the Pancreatic Cancer Therapeutics Market with DelveInsight's Strategic Report @ Pancreatic Cancer Market Outlook- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Epidemiology Segmentation in the 7MM
• Total Pancreatic Cancer Incident Cases
• Pancreatic Cancer Molecular Alteration-specific Incident Cases
• Pancreatic Cancer Stage-specific Incident Cases

Download the report to understand which factors are driving Pancreatic Cancer epidemiology trends @ Pancreatic Cancer Prevalence- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Marketed Drugs

• LYNPARZA (olaparib): AstraZeneca
LYNPARZA (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumors harboring a deficiency in homologous recombination repair, such as mutations in BRCA1 and/or BRCA2. In December 2019, AstraZeneca announced that LYNPARZA (olaparib) had been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works upon increasing the ability of the body's immune system to help detect and fight tumor cells. In May 2017, Merck announced that the US FDA had approved KEYTRUDA (pembrolizumab) to treat adult and pediatric patients with unrespectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pancreatic Cancer Emerging Drugs

• Mitazalimab (ADC-1013): Alligator Bioscience
Mitazalimab (previously ADC-1013) is an agonistic or stimulatory antibody that targets CD40, a receptor in the dendritic cells of the immune system, which are the cells that detect enemies such as cancer cells. Alligator recently reported top-line data from the clinical Phase II study with mitazalimab for the treatment of first-line metastatic pancreatic cancer, a disease well known for its poor prognosis and is on track to start its pivotal Phase III in 2025. In 2023, mitazalimab received Orphan Drug Designation in pancreatic cancer from the US FDA and Orphan Designation from the European Medicines Agency (EMA).

• Elraglusib (9 ING 41): Actuate Therapeutics
Elraglusib (a novel GSK-3 inhibitor) targets multiple molecular pathways in cancer that promote tumor growth and resistance to conventional cancer drugs such as chemotherapy. It is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. In August 2021, Actuate Therapeutics announced FDA Fast Track Designation for 9-ING-41 in the treatment of pancreatic cancer.

Learn more about the FDA-approved drugs for Pancreatic Cancer @ Drugs for Pancreatic Cancer Treatment- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Pancreatic Cancer Market Dynamics
The dynamics of the pancreatic cancer market are expected to evolve in the coming years. Combination chemotherapy remains a key treatment option for advanced and metastatic cases, offering short-term partial remissions or disease stability in newly diagnosed patients. Meanwhile, the growing identification of targetable germline and somatic alterations, along with the routine integration of genetic testing, is enhancing personalized treatment strategies. Additionally, multi-modal immunotherapeutic approaches, currently under clinical investigation, have demonstrated safety, encouraging further research into alternative strategies.

Scope of the Pancreatic Cancer Market Report
• Coverage- 7MM
• Pancreatic Cancer Companies- AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, and others.
• Pancreatic Cancer Therapies- Napabucasin, Gemcitabine, Parvovirus H-1 (H-1PV), AG-013736, Antroquinonol, Lanreotide autogel 120 mg and others.
• Pancreatic Cancer Market Dynamics: Pancreatic Cancer Market Drivers and Barriers
• Pancreatic Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Pancreatic Cancer Drugs in development @ Pancreatic Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Pancreatic Cancer-Market Overview at a Glance
4. Executive Summary of Pancreatic Cancer
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Pancreatic Cancer: Seven Major Market Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/sample-request/trichotillomania-ttm-market
Medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.